Characterizing Expanded Access and Compassionate Use Programs for Experimental Drugs

Miller JE, Ross JS, Moch KI, Caplan AL. Characterizing expanded access and compassionate use programs for experimental drugs. (2017). BMC Res Notes. DOI: 10.1186/s13104-017-2687-5.

Most (76%) provided drugs in expanded access programs eventually received FDA approval. Thus, provided drugs in registered expanded access programs are, more times than not, eventually deemed safe by the FDA.